127 related articles for article (PubMed ID: 12825876)
1. Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C.
Nøjgaard C; Johansen JS; Krarup HB; Holten-Andersen M; Møller A; Bendtsen F;
Scand J Gastroenterol; 2003 Jun; 38(6):659-65. PubMed ID: 12825876
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
[TBL] [Abstract][Full Text] [Related]
3. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.
Leroy V; Monier F; Bottari S; Trocme C; Sturm N; Hilleret MN; Morel F; Zarski JP
Am J Gastroenterol; 2004 Feb; 99(2):271-9. PubMed ID: 15046217
[TBL] [Abstract][Full Text] [Related]
4. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C.
Mitsuda A; Suou T; Ikuta Y; Kawasaki H
J Hepatol; 2000 Apr; 32(4):666-72. PubMed ID: 10782917
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.
Saitou Y; Shiraki K; Yamanaka Y; Yamaguchi Y; Kawakita T; Yamamoto N; Sugimoto K; Murata K; Nakano T
World J Gastroenterol; 2005 Jan; 11(4):476-81. PubMed ID: 15641129
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease.
Nøjgaard C; Johansen JS; Christensen E; Skovgaard LT; Price PA; Becker U;
J Hepatol; 2003 Aug; 39(2):179-86. PubMed ID: 12873813
[TBL] [Abstract][Full Text] [Related]
7. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.
Fontana RJ; Bonkovsky HL; Naishadham D; Dienstag JL; Sterling RK; Lok AS; Su GL;
Clin Gastroenterol Hepatol; 2009 Feb; 7(2):219-26. PubMed ID: 19068241
[TBL] [Abstract][Full Text] [Related]
8. Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C.
Flisiak R; Jaroszewicz J; Lapinski TW; Flisiak I; Prokopowiczi D
World J Gastroenterol; 2005 Nov; 11(43):6833-8. PubMed ID: 16425392
[TBL] [Abstract][Full Text] [Related]
9. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C.
Fontana RJ; Goodman ZD; Dienstag JL; Bonkovsky HL; Naishadham D; Sterling RK; Su GL; Ghosh M; Wright EC;
Hepatology; 2008 Mar; 47(3):789-98. PubMed ID: 18175357
[TBL] [Abstract][Full Text] [Related]
10. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.
Kasahara A; Hayashi N; Mochizuki K; Oshita M; Katayama K; Kato M; Masuzawa M; Yoshihara H; Naito M; Miyamoto T; Inoue A; Asai A; Hijioka T; Fusamoto H; Kamada T
J Hepatol; 1997 Mar; 26(3):574-83. PubMed ID: 9075665
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.
Tanwar S; Trembling PM; Hogan BJ; Srivastava A; Parkes J; Harris S; Grant P; Nastouli E; Ocker M; Wehr K; Herold C; Neureiter D; Schuppan D; Rosenberg WM
Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):289-296. PubMed ID: 27906753
[TBL] [Abstract][Full Text] [Related]
12. Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha.
Leroy V; De Traversay C; Barnoud R; Hartmann JD; Baud M; Ouzan D; Zarski JP
J Hepatol; 2001 Jul; 35(1):120-6. PubMed ID: 11495029
[TBL] [Abstract][Full Text] [Related]
13. Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN.
Fabris P; Marranconi F; Bozzola L; Biasin MR; De Lazzari F; Plebani M; Benedetti P; Tositti G; Pellizzer G; Stecca C; de Lalla F
J Gastroenterol; 1999 Jun; 34(3):345-50. PubMed ID: 10433010
[TBL] [Abstract][Full Text] [Related]
14. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
[TBL] [Abstract][Full Text] [Related]
15. Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha.
Lebensztejn DM; Sobaniec-Lotowska ME; Kaczmarski M; Voelker M; Schuppan D
World J Gastroenterol; 2006 Jun; 12(21):3338-43. PubMed ID: 16733849
[TBL] [Abstract][Full Text] [Related]
16. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis.
Rath T; Roderfeld M; Güler C; Wenzel C; Graf J; Beitinger F; Roeb E; Zachoval R
Scand J Gastroenterol; 2011 Nov; 46(11):1369-80. PubMed ID: 21905976
[TBL] [Abstract][Full Text] [Related]
17. TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma.
Ulrich D; Noah EM; von Heimburg D; Pallua N
Plast Reconstr Surg; 2003 Apr; 111(4):1423-31. PubMed ID: 12618601
[TBL] [Abstract][Full Text] [Related]
18. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
19. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection.
Valva P; Casciato P; Diaz Carrasco JM; Gadano A; Galdame O; Galoppo MC; Mullen E; De Matteo E; Preciado MV
PLoS One; 2011; 6(8):e23218. PubMed ID: 21858035
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of non-invasive serum markers for predicting liver fibrosis in Egyptian patients with chronic HCV infection.
El Guesiry D; Moez P; Hossam N; Kassem M
Egypt J Immunol; 2011; 18(2):1-12. PubMed ID: 23082465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
